Description
Meltix is a combination tablet manufactured by Navana Pharmaceuticals Ltd., containing Flupentixol (0.5 mg) and Melitracen (10 mg). This formulation is primarily used to treat various depressive and anxiety-related disorders, including psychogenic depression, depressive neuroses, masked depression, menopausal depression, and psychosomatic conditions accompanied by anxiety and apathy. Flupentixol, a neuroleptic with anxiolytic and antidepressant properties, works by blocking dopamine receptors in the brain. Melitracen, a tricyclic antidepressant, enhances the activity of serotonin and norepinephrine by inhibiting their reuptake. Together, these compounds provide a synergistic effect, addressing both depressive symptoms and anxiety. The typical dosage for adults is 2 tablets daily, taken in the morning and at noon. In severe cases, the morning dose may be increased to 2 tablets. Elderly patients are usually prescribed 1 tablet in the morning. Maintenance doses are typically 1 tablet daily. It's important to note that Meltix should not be used during the immediate recovery phase after a myocardial infarction, in patients with untreated narrow-angle glaucoma, or in those who have received monoamine oxidase inhibitors (MAOIs) within the past two weeks. Common side effects are rare but may include transient restlessness and insomnia. As with all medications, it should be used under the guidance of a healthcare professional
Change Language